<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204057</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-1901</org_study_id>
    <nct_id>NCT04204057</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy
      and safety of Tenalisib in 61 patients with CLL who have relapsed or are refractory after at
      least one prior therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tenalisib is a highly specific and orally available dual PI3K δ/γ inhibitor. Pre-clinical
      experiments demonstrated that Tenalisib is highly effective in killing primary CLL cells in
      vitro. A Phase II study is planned to evaluate the efficacy and safety of Tenalisib in
      patients with relapsed/refractory CLL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in 61 patients with CLL who have relapsed or are refractory after at least one prior therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (open label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>7 Months</time_frame>
    <description>Overall response rate (ORR): ORR is defined as sum of CR and PR rates as defined by iwCLL guideline for CLL (Hallek et al. 2018).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>7 Months</time_frame>
    <description>Duration of response (DOR): DOR is defined as the interval from the first documentation of CR/PR to first documentation of definitive disease progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE criteria v5.0</measure>
    <time_frame>7 Months</time_frame>
    <description>Safety and tolerability of Tenalisib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>7 months</time_frame>
    <description>Progression-free survival (PFS): PFS is defined as the interval from first dose to first documentation of definitive disease progression or death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Tenalisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib 800 mg BID, Orally</description>
    <arm_group_label>Tenalisib</arm_group_label>
    <other_name>RP6530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with diagnosis of B-cell CLL

          2. Disease status defined as refractory to or relapsed after at least one prior therapy.

          3. Presence of measurable lymphadenopathy presence of &gt; 1 nodal lesion

          4. ECOG performance status ≤ 2.

          5. Adequate bone marrow, liver, and renal function

        Exclusion Criteria:

          1. Richter's (large cell) transformation, or PLL transformation.

          2. Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5
             half-lives (whichever is shorter).

          3. Prior exposure to drug that inhibits PI3K

          4. Patient with ASCT/Allo-SCT receiving treatment for active GVHD.

          5. Ongoing severe systemic bacterial, fungal or viral infection.

          6. Central nervous system (CNS) involvement of leukemia or lymphoma.

          7. Ongoing immunosuppressive therapy including systemic corticosteroids.

          8. Known history of severe liver injury as judge by investigator.

          9. Any severe and/or uncontrolled medical conditions or other conditions that could
             affect patient participation

         10. Women who are pregnant or lactating.

         11. Known seropositive requiring anti-viral therapy for i. human immunodeficiency virus
             (HIV) infection. ii. hepatitis B virus (HBV) infection iii. hepatitis c virus (HCV)
             infection iv. active CMV infection

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prajak Barde, MD</last_name>
    <phone>+41 32 580 0113</phone>
    <email>pjb@rhizen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Dr Georgi Stranski&quot; Ltd.,</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay Tzvetkov, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sv Ivan Rilski&quot; Ltd</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atanas Radinoff, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ltd. M.Zodelava Hematology Centre</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamia Zodelava, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medivest - Institute of Hematology and Transfusiology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genadi Iosava, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.</name>
      <address>
        <city>Chorzow</city>
        <zip>41-503</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Grosicki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadeusz Robak, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphoinositide 3-kinase</keyword>
  <keyword>Pi3k Delta and gamma inhibitor</keyword>
  <keyword>Tenalisib</keyword>
  <keyword>Leukemia, Lymphocytic, Chronic, B-Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

